GlassScriptPhysician profile
Amouaz A Sbei
NPI 1679910608
$7,054.31
in general payments reported to CMS, 2019-2025
46 companies · $995 in 2025
The $995 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $670 · 2021: $971 · 2022: $1,491 · 2023: $971 · 2024: $969 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,162.14 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Novartis Pharmaceuticals Corporation | $731.21 | 2019-2025 | |
| Biogen, INC. | $554.11 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Abbvie INC. | $489.17 | 2021-2025 | Vraylar |
| Emd Serono, INC. | $445.41 | 2019-2025 | Mavenclad |
| Neurelis, INC. | $241.78 | 2021-2025 | Valtoco |
| Pfizer INC. | $236.18 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $233.17 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Acorda Therapeutics, INC | $217.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $204.33 | 2019-2023 | Ponvory |
| Supernus Pharmaceuticals, INC. | $202.14 | 2019-2021 | |
| Genzyme Corporation | $200.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.95 | 2022-2025 | Hyqvia, Gammagard |
| Amgen INC. | $186.41 | 2019-2024 | Aimovig |
| Otsuka America Pharmaceutical, INC. | $184.91 | 2023-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amouaz Sbei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.